Internationally renowned
Now in its 16th year of publication, the hugely successful Regulatory Rapporteur journal is well received throughout the regulatory community. The consistently high-quality content makes it a must-read monthly journal for our members and their associates.
The reach of Regulatory Rapporteur readership continues to grow as TOPRA membership expands, both in terms of numbers and geographical location.
A competitive reach
Our readership is diverse, and in terms of purchasing ownership it is read by both the customer and the consumer; decision-makers and budget-holders interested in a broad range of services ranging from medical devices, translation services and vacancies from across the industry.
Leading organisations such as Pfizer, Aspen, Gilead and DWL have regularly advertised their services on our pages.
Our members’ perspective
More than 61% of TOPRA members stated in a survey that they find Regulatory Rapporteur the most useful publication in their work and almost 60% of members stated that they find it the most authoritative journal in regulatory affairs.
Our clients’ perspective
‘DWL provides a specialist translation service to the pharmaceutical industry especially in the fields of regulatory affairs and clinical research.
Regulatory Rapporteur is always our first choice of advertising medium as its readership, the professional in regulatory affairs, is an important part of our market’
- Samuel J Wirth, Managing Director, DWL
Editorial themes for 2019
| February |
Advanced therapy medicinal products
|
| March |
Antimicrobial resistance
|
|
April
|
New technologies
|
|
May
|
Medical devices |
|
June
|
Clinical trials |
|
July/August
|
Paediatrics
|
|
September
|
Focus on Ireland
|
October
|
Serialisation (to combat falsified medicines)
|
November
|
North America |
| December |
TOPRA Annual Symposium issue |
Want to know more?
I’m interested in advertising in Regulatory Rapporteur